Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation
DAIC
MARCH 28, 2024
a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. Epub 2020 Jan 19. 2020 Jan 28;1747493020905964. 2020 June;127(1):4-20. Food & Drug Administration ( FDA ). Int J Stroke.
Let's personalize your content